Posted by Michael Wonder on 16 Mar 2017
EMA publishes updated list of applications for new human medicines under evaluation by the CHMP
16 March 2017 - This document lists information on applications for centralised marketing authorisation for human medicines that the EMA has received for evaluation.
It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the CHMP. For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.
This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on 7 March 2017.
